Fri, Mar 6, 2015, 5:42 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

IGI, Laboratories, Inc. Message Board

sdhoolteach2000 158 posts  |  Last Activity: 3 hours ago Member since: Jun 20, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Nite Holding the Ask

    by sdhoolteach2000 7 hours ago
    sdhoolteach2000 sdhoolteach2000 3 hours ago Flag

    Nite has moved! Now at $0.26 on the Ask.

  • sdhoolteach2000 sdhoolteach2000 3 hours ago Flag

    wily, the the specific portion of the vlp protrudes from the (P) domain as a structure that sticks out like a spike.Therefore in appears it maybe a target for our technology. What do you think now?

  • sdhoolteach2000 sdhoolteach2000 4 hours ago Flag

    True, but VLP'S may be able to also bind to a specific domain on the nanoparticle.

  • sdhoolteach2000 sdhoolteach2000 4 hours ago Flag

    It appears another opportunity exists to develop a vaccine that would address an unmet need and provide a large market for Novavax. Novavax's technology is applicable in areas of known and unknown diseases.

    We are in the right place at the right time and in the right field.

  • The Norovirus, the one that causes excessive vomiting and diarrhea, is disassembled by VLP's and it appears Novavax's RSV technology could be used to bind to a hidden domain on the virus, disassemble it, and thereby render it harmless. WOW!!
    Norovirus is highly contagious and travelers on sea cruise ships,at times, contract it.
    As of now there is no vaccine to prevent the virus.

    We are in the right place at the right time an in the right field

  • Reply to

    warrants

    by drpiano5 5 hours ago
    sdhoolteach2000 sdhoolteach2000 5 hours ago Flag

    You have to know when to hold them and know when to fold them, I believe it's a too short a time to hold them so that I won't have to decide when to fold them.

  • sdhoolteach2000 by sdhoolteach2000 7 hours ago Flag

    Nite is holding firm on the Ask at $0.25. Nite's attempting to keep the Ask in the $0.25 range. It appears it's becoming more difficult for Nite to do so.

  • Reply to

    Seller

    by sdhoolteach2000 Mar 5, 2015 11:08 AM
    sdhoolteach2000 sdhoolteach2000 Mar 5, 2015 1:34 PM Flag

    wily, after an early encouraging start trading turned sour and remains sour.

  • sdhoolteach2000 by sdhoolteach2000 Mar 5, 2015 12:38 PM Flag

    JAMA published the results and side effects VSV-ZEBOLA Ebola vaccine on a single person. The patient survive Ebola but not without severe side effects. The side effects included severe fever,nausea,malaise, muscle painchills,and joint Pain. the vaccine was produced in Canada and the results suggest a vaccines with a safer profile is much needed.

  • Reply to

    Seller

    by sdhoolteach2000 Mar 5, 2015 11:08 AM
    sdhoolteach2000 sdhoolteach2000 Mar 5, 2015 11:29 AM Flag

    The trading in the $9.10 area was much better today.

  • sdhoolteach2000 by sdhoolteach2000 Mar 5, 2015 11:08 AM Flag

    Do we have a large sell as we did on Tuesday? If so why?

  • sdhoolteach2000 by sdhoolteach2000 Mar 4, 2015 1:11 PM Flag

    Myelin-maker: How an FDA-approved drug boosts myelin synthesis

    Transplanted human stem cells treated with drug boost myelin synthesis and improve auditory function in a preclinical study

    University at Buffalo
    IMAGE

    IMAGE: The brainstem of a myelin-deficient mouse that received a transplant of human OPCs a few days after birth and was then treated with the drug solifenacin. Daily treatment enhanced the... view more

    Damage to myelin, the fatty insulator that enables communication between nerve cells, characterizes multiple sclerosis (MS) and other devastating neurological diseases.

    The damage doesn't come all at once: There is a "honeymoon" period during which some regeneration of myelin, called remyelination, does occur, but this ability to regenerate dissipates as the disease progresses and the patient ages.

    Now, a University at Buffalo researcher has discovered a way to keep that kind of remyelination going, using a drug that's already on the market.

    A paper describing the research results was published this week in the Journal of Neuroscience.

    "We have identified a new drug target that promotes stem cell therapy for myelin-based disease, such as MS," says lead author Fraser J. Sim, PhD, assistant professor in the Department of Pharmacology and Toxicology in the University at Buffalo School of Medicine and Biomedical Sciences.

    The study shows it is possible to boost myelination by targeting human oligodendrocyte progenitor cells with solifenacin, an anti-muscarinic drug that currently is approved and marketed to treat overactive bladder.

    "Our hypothesis is that in MS, the oligodendrocyte progenitor cells seem to get stuck," Sim explains. "When these cells don't mature properly, they don't differentiate into myelinating oligodendrocytes."

  • Reply to

    Is Erck Holding Out On Ebola?

    by sdhoolteach2000 Mar 3, 2015 10:04 AM
    sdhoolteach2000 sdhoolteach2000 Mar 3, 2015 11:27 AM Flag

    We.re talking semantics and are on the same page.

  • sdhoolteach2000 sdhoolteach2000 Mar 3, 2015 10:24 AM Flag

    No,the article is not old it's new news. It's not an abstract that was reworked and as I said in yesterday's post RGRX would have a PR to spotlight the news and they have one out today. The news indicates a step forward by Dr. Chopp to announce a clinical trial using Tb-4. It may also signal another round of buying will begin by whomever is accumulating the stock.

  • sdhoolteach2000 by sdhoolteach2000 Mar 3, 2015 10:04 AM Flag

    There's a chance that Erck is holding out in accepting monies from an NGO until he finishes discussions with big pharma on the funding of the Ebola vaccine. It makes sense to think of AstraZeneca as being a part of the talks because the Ebola vaccine is being made similar to the RSV vaccine. AstraZeneca sells Synergas, their treatment for RSV, with sales of a billion dollars. Erck states an RSV vaccine will be the best selling vaccine of all time and Pfizer has a vaccine that brings in $6.25 billion annually. AstraZenica has just completed a multi-billion buyout to shore up its impressive respiratory portfolio and it's increasing their North American presence.
    In short, AstraZenica and Novavax are a natural fit and Astrazenica would get it's foot in the door by funding Novavax's Ebola vaccine.

    We are in the right place at the right time and in the right field.

  • sdhoolteach2000 sdhoolteach2000 Mar 3, 2015 9:14 AM Flag

    The latest article is not an abstract. It's a call for a new medical approach to stroke and neurological diseases one that treats with TB-4 and not with TPA. The tone of Chopp's comments is to inform the medical community of TB-4 and importantly to give them a sense that he's about to undertake a new initiative using TB-4. Reading between the lines he's suggesting he's going to announce a human phase 1 clinical for stroke using TB-4.

  • Reply to

    The Market Awaits

    by sdhoolteach2000 Mar 2, 2015 10:16 AM
    sdhoolteach2000 sdhoolteach2000 Mar 2, 2015 6:02 PM Flag

    Erck, set the ceiling high, that's for sure.

  • Reply to

    The Market Awaits

    by sdhoolteach2000 Mar 2, 2015 10:16 AM
    sdhoolteach2000 sdhoolteach2000 Mar 2, 2015 5:59 PM Flag

    yup, that's what nvax is about.

  • Reply to

    The Market Awaits

    by sdhoolteach2000 Mar 2, 2015 10:16 AM
    sdhoolteach2000 sdhoolteach2000 Mar 2, 2015 2:03 PM Flag

    Without any news on Ebola it will be difficult to stabilize the price step down in the near future. The market needs more information on Ebola to reverse the downtrend,now.

  • Dr. Chopp proposes a novel new treatment for stroke and neurological diseases. In his article published online in Expert Opinion on Biological Therapy he alludes to TB-4 as a synthetic version of a peptide that occurs naturally in humans and other mammals. He states that in animal studies "TB-4 is highly effective for the treatment of neurological diseases in part by increasing the formation of protective myelin around nerve fibers in the central and peripheral nervous systems." Dr. chopp's main point is that it's about time to reconsider how we think about treating neural injury and disease.
    From what I've read he's a man whom is interested in furthering his research on TB-4 and may in the near future express how he's going to do it.
    Regenerx should spotlight the article with a press release in the immediate future.

IG
9.01-0.42(-4.45%)Mar 6 4:04 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.